Novartis Heart Drug Pelacarsen Fails Key Trial, Shaking Lp(a) Treatment Hopes

Novartis Pelacarsen, a highly anticipated heart disease drug developed with Ionis Pharmaceuticals, failed its crucial Phase 3 clinical trial, sending shockwaves through the pharmaceutical industry and casting a shadow over a promising new class of therapies. The drug, aimed at treating elevated lipoprotein(a), or Lp(a), a genetic risk factor for heart disease, did not reduce major cardiovascular events like heart attacks and strokes, despite successfully lowering Lp(a) levels. This unexpected outcome marks a significant blow to a potential breakthrough treatment and led to immediate stock drops for both Novartis and its partner, Ionis Pharmaceuticals. The failure of Pelacarsen in the Lp(a)HORIZON trial is a major disappointment for millions globally, as about one in five people have elevated Lp(a) levels, and there are currently no approved targeted treatments for this inherited cardiovascular risk factor. This trial was widely seen as a critical test for the entire Lp(a)-lowering approach, a field where other major pharmaceutical companies like Amgen and Eli Lilly are also investing heavily with their own siRNA-based drugs, olpasiran and lepodisiran, respectively. The results raise fundamental questions about whether simply reducing Lp(a) translates into real-world cardiovascular benefits, or if deeper or different methods of reduction are needed, especially since the trial participants were already receiving standard-of-care treatments for heart disease. Novartis and Ionis Pharmaceuticals are expected to present the full Lp(a)HORIZON trial data at an upcoming medical congress, which will provide more detailed insights into why the drug missed its primary goal. The pharmaceutical industry will be closely watching for how this setback influences the development strategies of competing Lp(a)-targeting drugs and the broader research into advanced cardiovascular disease treatments. While the immediate future for Pelacarsen is uncertain, the scientific community will continue to explore other avenues to address this inherited and prevalent cardiovascular risk.